Recordati Industria Chimica e Farmaceutica posted higher net income for the first half of 2026 and confirmed its full-year guidance. Net income rose to 269.67 million euros from 216.12 million euros a year earlier, with earnings per share of 1.292 euros compared to 1.033 euros. Adjusted net income climbed to 349.85 million euros from 327.76 million euros, while EBITDA increased to 540.20 million euros from 496.35 million euros. Operating income advanced to 419.21 million euros from 331.03 million euros, and net revenue grew to 1.41 billion euros from 1.32 billion euros. The company still expects full-year 2026 net revenue between 2,730 million euros and 2,800 million euros, EBITDA between 995 million euros and 1,030 million euros, and adjusted net income between 655 million euros and 685 million euros.
RecordatiRecordati reported higher first-half earnings and maintained full-year guidance, indicating strong financial performance.